STOCKHOLDERS’ EQUITY |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| STOCKHOLDERS’ EQUITY | NOTE 7— STOCKHOLDERS’ EQUITY
PUBLIC OFFERING
On January 12, 2024 the underwriter exercised its over-allotment option as to shares of common stock for net proceeds after discounts and commission of $192,156.
SHARES TO BE ISSUED
As of September 30, 2025 and 2024, there were and , respectively, shares to be issued whose issuance has been deferred under the terms of employment and consulting agreements with officers and directors and other employees of Milestone Scientific. Such shares will be issued to each party upon termination of their employment or other relationship with the Company.
As of September 30, 2025 and 2024, there were and , respectively, shares to be issued to non-employees, that will be issued to non-employees for services rendered. The number of shares was fixed by contract before the date of grant, subject to performance, and were fully earned upon the grant date.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||